Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
1.6B USD
Enterprise value
1.5B USD
Full-time employees
3,485
Overall health
Strength:growing faster than most peersgrowing faster than peers
Drawback:its share price swings more than most peers’ (beta 0.99 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.99 vs peers 0.63)
Drawback:less short-term liquidity (current ratio 1.64 vs a peer median of 2.59)less liquidity (current ratio 1.64 vs peers 2.59)
About average:profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk
Ranks #604 of 1,157 healthcare companies (bottom 48%)
Stock pay outran buybacks. Stock-based pay expense $139M vs $78M spent repurchasing shares over the 3 fiscal years to 2025. Shares outstanding changed +1.9% from December 2022 to July 2026.
Over three fiscal years Omnicell recorded $139M of stock-based pay expense and spent $78M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Omnicell recorded $139M of stock-based pay expense and spent $78M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Cash flow well above reported profit. Free cash flow is 3.6× reported profit.
Free cash flow is 3.6× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 54 → 55
Share price -3.5%+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.33Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Omnicell
Is Omnicell getting weaker?
Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 51/100 since Oct 28, 2026.
How is Omnicell valued vs its peers?
Priced about in line with its peers. Valuation scores 55/100 against 1,393 healthcare peers.
Is Omnicell growing?
Yes, faster than most of its peers. Growth scores 61/100 against 1,393 healthcare peers.Earnings per share growth 70.5% vs a peer median of 9.8% (stronger than 84% of peers).Earnings per share growth 70.5% vs peers 9.8% (stronger than 84% of peers).3-year revenue growth 0.3% vs a peer median of 5.8% (weaker than 71% of peers).3-year revenue growth 0.3% vs peers 5.8% (weaker than 71% of peers).
How profitable is Omnicell?
About as profitable as its peers. Profitability scores 47/100 against 1,393 healthcare peers.
How risky is Omnicell?
Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.99 vs a peer median of 0.63 (weaker than 71% of peers).Beta 0.99 vs peers 0.63 (weaker than 71% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
1.2B USD
1.2B USD
+1.8%
Net income (12 months)
20.4M USD
39.1M USD
+91.3%
Operating margin
2.7%
4.6%
+1.9 pts
Free cash flow (12 months)
114.2M USD
142.6M USD
+24.9%
Cash
239.2M USD
292.2M USD
+22.1%
Shares outstanding
45.5M
45.6M
+0.3%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
49.0%
45.4%
43.3%
42.3%
42.5%
▲ 0.1 pts
Operating margin
7.9%
-0.2%
-3.0%
0.0%
0.4%
▲ 0.4 pts
Net margin
6.9%
0.4%
-1.8%
1.1%
0.2%
▼ 1.0 pts
Return on assets (ROA)
3.6%
0.3%
-0.9%
0.6%
0.1%
▼ 0.5 pts
Return on equity (ROE)
6.8%
0.5%
-1.7%
1.0%
0.2%
▼ 0.8 pts
Free cash flow margin
17.9%
2.3%
12.2%
13.6%
7.3%
▼ 6.3 pts
Current ratio
0.89×
2.06×
2.52×
1.37×
1.43×
▲ 4.2%
Quick ratio
0.75×
1.71×
2.22×
1.22×
1.22×
▼ 0.4%
OMCL price history
Price history is added with the daily price update and will appear after the next one.